TABLE 1.
Characteristics of Study Design, HPV Status, and Persistence Definition for Studies Included in the Current Review
| Study characteristics | Jaisamrarn et al.42 (2013) | Skinner et al.43 (2016) | Schiffman et al.2 (2005) and Castle et al.47 (2009) | Gage et al.49 (2010) | Elfgren et al.48 (2017) | Kjaer et al.52 (2010) | Kitchener et al.51 (2014) and Gilham et al.50 (2019) | Sand et al.53 (2019) |
|---|---|---|---|---|---|---|---|---|
| Design | PRO; RT | PRO; RT | PRO; cohort | PRO; post hoc; cohort | PRO; post hoc; cohort | PRO; cohort | PRO; RT | PRO; cohort |
| Months of persistent infection | 6 | 6 and 12 | 12 (range = 9–21) | 12 | 12 (median = 19) | 24 | 36 | 36 |
| Age, y | ||||||||
| Median | — | nr; >25 | 37 | 23 | Range = 32–38 | 28 | 39.4 | 31 |
| Mean | 19.7 | — | — | — | — | — | ||
| Recruitment | 9,337 | 2,870 | 10,049 | 5,060 | 12,527 | 11,088 | 24,510 | 40,399 |
| Analysis | 4,825 | 2,838 | 7,278;a 2,282b | 671 | 6,257 | 7,482 | 24,510 | 5,528 |
| HPV(+) at baseline | 3,363 | 507 | 542 | 584 | 433; 341 | 1,222 | 3,813 | 2,875 |
| Specimen collection dates | 2004–2009 | 2006–2011 | 1993–1994 | 2000–2001 | 1997–2012 | 1991–1995 | 2001–2009 | 2002–2005 |
| Year follow-up ended | 2009 | 2014 | nr | 2002 | 2012 | 2007 | 2010–2015 | 2015 |
| Median follow-up | 4 y | 2 y | 5 y | 2 y | 13 y | 12.9 y | 6 y; 13 y | 8 y |
| Country | Multinational | Multinational | Costa Rica | United States | Sweden | Denmark | England, United Kingdom | Denmark |
| HPV assay | DEIA/LiPA25 | DEIA/LiPA25 | MY09/11 PCR | HC2; Line Blot | GP5+/6+ PCR | HC2; INNO-LiPA | LBA; LA; Pap√ of HC2 | HC2; INNO-LiPAv2 |
aTreatment based on colposcopic impression.
bIncluded use of AmpliTaq Gold polymerase.
LA, liner array; OBS, observational study; PCR, polymerase chain reaction; PRO, Prospective design; RETRO, retrospective design; RT, randomized clinical trial.